Amgen-Sanofi patent case divides makers of antibody drugs
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Amgen Inc’s battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.
